Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment

By Mark C. Via

SURVEY QUESTIONS

Objective: To illuminate trends in monoclonal antibody research

Participation: Individuals in R&D, business development, marketing and strategy at pharmaceutical and biotech companies, academia, and in government

1. Please classify your organization.
 
2. Please classify the work your organization does related to mAbs.

3. Under what functional area do your responsibilities fall?
 
4. How has the number of mAbs in your organization's pipeline changed over the past 5 years?
 
5. If the number of mAbs in your pipeline has increased, please indicate by how much
 
6. Has your organization's level of activity changed in the past 5 years in terms of creating, developing, or improving mAbs?
 
7. Does your organization plan to change its level of involvement with mAbs over the next 3 years?
 
8. In the past 20 years, about 20 mAbs have received regulatory approval. How many years do you expect it will take for another 20 mAbs to be approved?
 
9. What facets of mAb development pose the most significant challenges?
 
10. What will be the most important technologies for improving or accelerating mAb development in the next 5 years?
 
11. What will be the major improvements in mAb therapeutics over the next 5 years?
 
12. What disease areas do you feel will see significant treatment advances as a result of mAb development over the next 5 years?